- Home
- JNJ vs ABBV Comparison
JNJ vs ABBV Comparison
Compare JNJ & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNJ
- ABBV
- Stock Information
- Founded
- JNJ 1886
- ABBV 2012
- Country
- JNJ United States
- ABBV United States
- Employees
- JNJ N/A
- ABBV N/A
- Industry
- JNJ Biotechnology: Pharmaceutical Preparations
- ABBV Biotechnology: Pharmaceutical Preparations
- Sector
- JNJ Health Care
- ABBV Health Care
- Exchange
- JNJ Nasdaq
- ABBV Nasdaq
- Market Cap
- JNJ 449.6B
- ABBV 403.2B
- IPO Year
- JNJ 1944
- ABBV N/A
- Fundamental
- Price
- JNJ $186.25
- ABBV $212.33
- Analyst Decision
- JNJ Buy
- ABBV Buy
- Analyst Count
- JNJ 16
- ABBV 20
- Target Price
- JNJ $196.19
- ABBV $233.89
- AVG Volume (30 Days)
- JNJ 8.4M
- ABBV 5.4M
- Earning Date
- JNJ 10-14-2025
- ABBV 10-31-2025
- Dividend Yield
- JNJ 2.79%
- ABBV 3.27%
- EPS Growth
- JNJ 71.26
- ABBV N/A
- EPS
- JNJ 10.35
- ABBV 1.32
- Revenue
- JNJ $92,149,000,000.00
- ABBV $59,644,000,000.00
- Revenue This Year
- JNJ $6.63
- ABBV $10.00
- Revenue Next Year
- JNJ $5.31
- ABBV $9.17
- P/E Ratio
- JNJ $18.00
- ABBV $160.50
- Revenue Growth
- JNJ 5.08
- ABBV 7.40
- 52 Week Low
- JNJ $140.68
- ABBV $163.81
- 52 Week High
- JNJ $194.48
- ABBV $244.81
- Technical
- Relative Strength Index (RSI)
- JNJ 45.96
- ABBV 32.19
- Support Level
- JNJ $184.66
- ABBV $224.04
- Resistance Level
- JNJ $189.50
- ABBV $229.65
- Average True Range (ATR)
- JNJ 2.51
- ABBV 4.16
- MACD
- JNJ -1.06
- ABBV -2.17
- Stochastic Oscillator
- JNJ 16.19
- ABBV 1.30
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.